Jefferies analyst Akash Tewari raised the firm’s price target on Argenx to $465 from $455 and keeps a Buy rating on the shares. Argenx’s subQ efgartigimod was approved by the FDA in generalized myasthenia gravis, with Jefferies telling investors in a research note that the label looks “fine” and generally in line with the IV.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARGX:
- Halozyme says Argenx receives FDA approval for Vyvgart Hytrulo with Enhanze
- argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
- Argenx announces FDA approval of VYVGART Hytrulo
- Argenx announces plan to advance to second dose cohort with ARDA study
- argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue